EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Radiolabelled Cyclodextrins for the Positron Emission Tomography Imaging of Breast Cancer: Preclinical Perspectives

Tamás Sass iD, Judit P Szabó iD, Renáta Adél Dienes iD, Péter Árkosy iD, Gábor Opposits iD, István Jószai iD, Anikó Fekete iD, Ferenc Fenyvesi iD, István Hajdu iD, György Trencsényi iD, Zita Képes iD

Clinical and Translational Science · 2025

DOI: 10.1111/cts.70379 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Tamás Sass und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Faculty of Medicine, University of Debrecen, Debrecen, Hungary. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Breast Neoplasms, Cyclodextrins, Radiopharmaceuticals. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Given the increasing incidence and mortality of breast cancer, the development of target‐specific imaging probes for early disease detection seems straightforward. Prostaglandin E2 (PGE2) and its receptors have a crucial role in tumor angiogenesis; therefore, radiolabelled cyclodextrins targeting such biomolecules may serve as selective vectors for positron emission tomography (PET) imaging of breast cancer. Herein, we aimed to monitor PGE2 production in MDA‐MB‐HER2‐positive and 4 T1 triple‐negative breast cancer xenografts using 68 Ga‐labeled randomly methylated beta cyclodextrin (RAMEB) and 2‐hydroxypropyl‐beta‐cyclodextrin (HPβCD) and PET technique. After the injection of [ 68 Ga]Ga‐NODAGA‐HPβCD and [ 68 Ga]Ga‐DOTAGA‐RAMEB, CB17 SCID mice bearing breast tumors underwent weekly PET imaging with subsequent quantitative data assessment and ex vivo biodistribution studies. Both cyclodextrin compounds were suitable to identify the tumors, though tracer accumulation varied with tumor size. Significantly higher [ 68 Ga]Ga‐NODAGA‐HPβCD uptake was observed in the MDA‐MB‐HER2+ tumors across all sizes (small, medium, and large‐sized) compared to the 4 T1 counterparts. In contrast, [ 68 Ga]Ga‐DOTAGA‐RAMEB accumulated to a greater extent in small and midsized 4 T1 tumors in comparison with size‐matched MDA‐MB‐HER2+ tumors, while it showed higher uptake in the large HER2+ lesions than in 4 T1. The presented results indicate notable radioactivity in both 4 T1 and MDA‐MB‐HER2+ tumors designating [ 68 Ga]Ga‐DOTAGA‐RAMEB and [ 68 Ga]Ga‐NODAGA‐HPβCD as effective PET probes for the identification of breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron-Emission TomographyBreast NeoplasmsCyclodextrinsRadiopharmaceuticalsAnimalsFemaleHumansMiceGallium RadioisotopesCell Line, TumorMice, SCIDTissue DistributionAcetatesXenograft Model Antitumor Assaysbeta-Cyclodextrins

Stichwörter der Autor:innen

angiogenesisbreast cancercyclodextrinpositron emission tomographypreclinicalprostaglandin E2radiopharmaceuticals

Substanzen

Gallium RadioisotopesCyclodextrinsRadiopharmaceuticalsAcetatesGallium-68beta-Cyclodextrins

Autor:innen und Institutionen

  • Department of Surgery, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Gyula Petrányi Doctoral School of Clinical Immunology and Allergology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Division of Nuclear Medicine and Translational Imaging, Department of Medical Imaging, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Department of Oncology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
  • Department of Molecular and Nanopharmaceutics, Faculty of Pharmacy, University of Debrecen, Debrecen, Hungary.

ORCID-Profile: Tamás Sass, Judit P Szabó, Renáta Adél Dienes, Péter Árkosy, Gábor Opposits, István Jószai, Anikó Fekete, Ferenc Fenyvesi, István Hajdu, György Trencsényi, Zita Képes

Zitieren

APA

Sass, T., Szabó, J. P., Dienes, R. A., Árkosy, P., Opposits, G., Jószai, I., Fekete, A., Fenyvesi, F., Hajdu, I., Trencsényi, G., & Képes, Z. (2025). Radiolabelled Cyclodextrins for the Positron Emission Tomography Imaging of Breast Cancer: Preclinical Perspectives. Clinical and Translational Science. https://doi.org/10.1111/cts.70379

Vancouver

Sass T, Szabó JP, Dienes RA, Árkosy P, Opposits G, Jószai I, et al. Radiolabelled Cyclodextrins for the Positron Emission Tomography Imaging of Breast Cancer: Preclinical Perspectives. Clinical and Translational Science. 2025. doi:10.1111/cts.70379

BibTeX
@article{Sass2025,
  author = {Sass, Tamás and Szabó, Judit P and Dienes, Renáta Adél and Árkosy, Péter and Opposits, Gábor and Jószai, István and Fekete, Anikó and Fenyvesi, Ferenc and Hajdu, István and Trencsényi, György and Képes, Zita},
  title = {Radiolabelled Cyclodextrins for the Positron Emission Tomography Imaging of Breast Cancer: Preclinical Perspectives},
  journal = {Clinical and Translational Science},
  year = {2025},
  doi = {10.1111/cts.70379}
}
Kostenlos starten →